



The Nifty ended 2.63% up at 16259.30. It opened on a flat note and moved up decisively after several sessions towards finishing off with a huge bullish body candle. Closing above 16100 suggesting further rise towards 16400 levels, midway resistance is placed around 16300 levels. We prefer buying on dips for the higher targets of 16400 and 16450 levels. Intraday trading range likely to be 16200-16400.

On the Nifty hourly chart, direction of the leading indicators pointing towards further rise. Intraday range likely to be 16200-16400.

Nifty patterns on multiple periods suggesting; ending above 16100 with a bullish candle suggesting reversal. Hence, buy on dips is advised. Oversold Index majors likely to play a critical role in the next round of recovery towards 16400 levels.

Nifty Crucial Supports & Resistances-

Supports- 16200, 16100 Resistances- 16300, 16400

Open Positional Calls-

- T+10 INST POSITIONAL BUY-
|Cash Segment| AXIS BANK @ 650-640, TGT- 700, Closing SL- Below 610
- T+10 INST POSITIONAL BUY-
|Cash Segment| HDFC BANK @ 1310-1300, TGT- 1400, Closing SL- Below 1250
- T+3 BUY-
|Cash Segment| INDUSIND BANK @ 890-880, TGT- 925, Closing SL- Below 865
- T+4 BUY-
|Cash Segment| BHEL @ 48, TGT- 52, Closing SL- Below 46
- T+10 INST POSITIONAL BUY-
|Cash Segment| SAIL @ 84-83, TGT- 93, Closing SL- Below 78
- T+2 BUY-
|Cash Segment| BANDHAN BANK @ 340-339, TGT- 349, Closing SL- Below 334
- T+4 BUY-
|Cash Segment| KOTAK BANK @ 1835-1830, TGT- 1890, Closing SL- closing below 1800
- T+2 BUY-
|Cash Segment| MC DOWELL @ 827-825, TGT- 845, Closing SL- Below 815
- BTST-
|Cash Segment| MOTHER SUMI @ 124.50-124, TGT- 128, Closing SL- below 122
- BTST-
|Options Segment| BANK NIFTY 26MAY 34800-CE @ 310-290, TGT- 400, SL- below 240
- BTST-
|Cash Segment| CAN BANK @ 203-202, TGT- 208, Closing SL- closing below 199
- BTST-
|Cash Segment| HCL TECH @ 1080, TGT- 1100, Closing SL- below 1070
- BTST-
|Cash Segment| IND HOTEL @ 230-229, TGT- 235, Closing SL - below 226

Key Contents	Page No.
Result Update	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks logged best day in over two months, aided by gains in metal, energy and oil and gas stocks. This is also the second best day for the Sensex and Nifty in over fifteen months as well as 2022.

Nifty index ended 2.63% higher at 16,259. The broader markets represented by the Nifty 500 Index ended 2.61% higher, ending at 13,926. Among the sectorial indices, all indices ended positive. Nifty Metal was the to gainer, gaining by 6.86%, followed by Nifty PSE gaining by 3.26%.

Hindalco was the top gainer, gaining by 9.58%, followed by Tata Steel and Coal India which gaining by 7.72% & 7.48%. Tata Consumer Products was the only loser, losing by 0.17%.

The Advance : Decline ratio stood at 1832:325

Market Turnover (In Crore) 17-05-2022

Name	Last	Previous
NSE Cash	55967.23	46863.04
NSE F&O	8451510.80	6789922.97
BSE Cash	3,722.94	3,129.98
BSE F&O	*NA	130.93

FII Derivatives Flow (In Crore) 16-05-2022*

Instrument	Purchase	Sale	Net
Index Future	3960.65	2980.19	980.46
Index Option	614919.45	616399.37	1479.92
Stock Future	15537.33	13497.99	2039.34
Stock Option	7643.59	7553.52	90.07

Institutional Flow (In Crore) 17-05-2022

Institution	Purchase	Sale	Net
FII	6128.11	8320.55	2192.44
DII	7315.14	5020.72	2294.42

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Hindalco Industries	9.58	1.28	37772554	15719840
Tata Steel	7.72	2.04	11287601	9847637
Coal India	7.48	8.53	28092052	14008370
JSW Steel	6.57	0.53	6309092	4556803
ONGC	6.29	5.63	17843200	17057330

NIFTY Top Losers


Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Tata Con Products	0.17	1.55	2536701	1282598

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.asp>

*Data not updated till 5:30PM

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	54318.47	1344.63	2.54	0.09	4.98	6.08	8.22
Nifty	16259.30	417.00	2.63	0.12	5.32	5.89	7.62
BSE M Cap	22700.87	555.77	2.51	2.06	9.14	5.27	8.92
BSE S Cap	26318.08	712.09	2.78	0.92	10.85	5.91	16.66
Nifty MC 100	28172.90	747.40	2.73	2.27	7.55	2.63	11.50
BSE Auto	24841.66	572.50	2.36	4.01	1.57	4.13	7.23
BSE Capgoods	26189.77	783.58	3.08	0.95	6.81	7.89	19.22
BSE FMCG	13735.63	286.40	2.13	1.47	2.43	2.31	5.53
BSE Metal	19437.24	1376.19	7.62	1.60	15.39	3.67	0.01
BSE Oil&Gas	19181.78	652.14	3.52	3.19	3.35	6.09	20.55
BSE Healthcare	22650.20	296.03	1.32	1.08	9.00	5.81	5.97
BSE Power	4402.77	99.22	2.31	2.49	9.71	14.03	60.01
BSE Realty	3198.05	60.82	1.94	2.94	12.15	10.29	30.61
BSE ConsDur	37710.95	920.78	2.50	0.94	11.57	11.20	16.06
BSE Bank	39644.21	856.49	2.21	0.21	6.39	7.94	2.89
BSE IT	30568.30	775.46	2.60	0.42	11.65	11.16	16.05

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	2.92	0.03	1.20	2.48	3.15	48.70	76.90
UK	1.82	0.09	5.26	1.46	3.60	24.47	110.52
Brazil	5.78	0.00	0.02	2.02	7.79	13.18	51.77
Japan	0.25	0.00	0.41	0.41	2.08	8.85	189.41
Australia	3.41	0.02	0.62	4.49	14.65	54.28	94.46
India	7.37	0.05	0.66	1.68	2.09	10.37	23.32
Switzerland	0.79	0.05	6.60	16.56	7.49	194.05	753.72
Germany	1.01	0.08	8.22	1.40	20.43	338.96	981.74

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	77.56	0.12	0.15	0.31	1.68	3.16	5.60
USD Index	103.24	0.95	0.91	0.65	2.91	7.77	14.50
YUAN	6.72	0.06	0.91	0.15	5.32	5.74	4.25
GBP	1.25	0.02	1.39	1.41	4.06	8.27	11.63
EUR	1.05	0.01	1.07	0.16	2.19	7.17	13.22
YEN	129.28	0.12	0.09	0.91	1.77	11.09	15.52

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	3085.00	19.00	0.61	4.97	44.36	63.57	8.02
Baltic Dirty	1125.00	8.00	0.71	3.60	34.36	62.10	84.43
SG Dubai HY	26.20	2.21	7.78	3.25	23.24	285.86	5037.25

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	32223.42	26.76	0.08	0.07	6.47	6.09	6.13
Nasdaq	11662.79	142.21	1.20	0.34	12.65	14.97	12.83
S&P 500	4008.01	15.88	0.39	0.42	8.76	8.50	3.73
FTSE100	7525.30	59.49	0.80	3.88	1.21	0.17	6.99
CAC40	6421.96	78.40	1.24	5.06	2.48	7.49	0.92
DAX	14164.15	207.09	1.48	4.70	0.05	7.18	7.96
Mexico IPC	50563.98	984.08	1.98	3.07	6.66	4.08	2.41
Brazil Bovespa	108232.7	0.00	0.00	4.83	6.84	4.66	11.96
Russian RTS	1187.77	13.54	1.15	9.15	24.30	18.10	23.45
Japan Nikkei	26659.75	112.70	0.42	1.88	0.52	1.70	6.15
Hang Seng	20602.52	652.31	3.27	4.93	4.25	15.31	27.95
Taiwan Index	16056.09	155.05	0.98	0.03	4.99	11.94	0.56
Shanghai Comp	3093.70	19.95	0.65	1.91	3.19	11.37	12.34
KOSPI	2620.44	23.86	0.92	0.92	2.70	4.52	17.42
Malaysia KLCI	1548.60	4.19	0.27	0.04	2.06	3.40	2.68
Jakarta Comp	6644.47	46.47	0.70	3.84	8.67	3.60	13.88
Philippine SE	6594.66	92.54	1.42	1.88	5.74	11.11	5.60
Thai Exch	1614.49	30.11	1.90	0.62	3.21	5.76	3.04

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	115.27	1.14	1.00	15.62	7.84	25.70	74.05
BRENT Crude	115.41	1.26	1.10	12.73	4.24	31.71	78.30
Natural Gas	8.28	0.33	4.11	12.16	11.59	84.03	216.87

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1835.57	11.69	0.64	0.13	7.20	3.30	1.66
Silver(\$/Ounce)	21.84	0.23	1.07	2.76	14.47	8.32	22.43
Aluminium	2802.75	42.25	1.53	3.07	14.33	14.81	14.95
Copper	9255.50	70.90	0.77	0.16	10.12	7.77	9.39
Zinc	3564.50	71.25	2.04	1.64	20.35	0.89	22.08
Lead	2077.24	32.89	1.61	3.01	14.88	11.57	2.83

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	221.70	3.10	1.38	8.78	0.92	11.02	43.68
Cotton	150.46	0.19	0.13	5.26	6.93	28.95	86.58
Sugar	19.70	0.02	0.10	6.26	1.65	11.68	24.21
Wheat	1224.25	23.25	1.86	12.03	10.84	52.98	83.82
Soybean	1652.75	3.75	0.23	3.80	0.75	3.72	21.66

GSK Pharma

Glaxosmithkline Pharmaceuticals reported a consolidated net profit of Rs 1,219.05 crore in Q4 FY22 as against a net profit of Rs 14.33 crore in Q4 FY21. Net sales during the quarter increased by 8.9% YoY to Rs 809.63 crore. Profit before tax (PBT) (before exceptional items) from continuing operations for the fourth quarter was Rs 178 crore, recording a growth of 6% YoY. GSK Pharma's consolidated net profit surged to Rs 1,694.72 crore in FY22 from Rs 358.15 crore in FY21. Net sales rose by 12% to Rs 3,278.03 crore in FY22 over FY21.

Greenply Industries

Greenply Industries reported consolidated quarterly numbers, Net Sales at Rs 448.55 crore in March 2022 up 13.07% from Rs. 396.70 crore in March 2021. Quarterly Net Profit at Rs. 28.97 crore in March 2022 up 1.17% from Rs. 28.64 crore in March 2021. EBITDA stands at Rs. 47.64 crore in March 2022 down 3.48% from Rs. 49.36 crore in March 2021. Greenply Ind EPS has increased to Rs. 2.36 in March 2022 from Rs. 2.34 in March 2021.

MCX India

MCX India reported consolidated quarterly numbers, Net Sales at Rs 106.46 crore in March 2022 up 9.79% from Rs. 96.97 crore in March 2021. Quarterly Net Profit at Rs. 36.53 crore in March 2022 down 4.97% from Rs. 38.44 crore in March 2021. EBITDA stands at Rs. 67.81 crore in March 2022 up 21.68% from Rs. 55.73 crore in March 2021. MCX India EPS has decreased to Rs. 7.18 in March 2022 from Rs. 7.55 in March 2021.

V I P Industries

Net profit of V I P Industries reported to Rs 12.39 crore in the quarter ended March 2022 as against net loss of Rs 3.78 crore during the previous quarter ended March 2021. Sales rose 46.46% to Rs 355.90 crore in the quarter ended March 2022 as against Rs 243.00 crore during the previous quarter ended March 2021. For the full year, net profit reported to Rs 66.93 crore in the year ended March 2022 as against net loss of Rs 97.49 crore during the previous year ended March 2021. Sales rose 108.47% to Rs 1289.51 crore in the year ended March 2022 as against Rs 618.56 crore during the previous year ended March 2021.

Bharti Airtel

Bharti Airtel reported consolidated net profit at Rs 2,007.8 crore, registering a jump of 164.46 per cent compared with Rs 759.2 crore in the same quarter last year. The telco said its consolidated EBITDA was at Rs 15,998 crore, with EBITDA margin at 50.8 per cent for the quarter, which is an improvement of 192 bps YoY.

Zydus Wellness

Net profit of Zydus Wellness rose 0.13% to Rs 133.30 crore in the quarter ended March 2022 as against Rs 133.13 crore during the previous quarter ended March 2021. Sales rose 5.73% to Rs 635.19 crore in the quarter ended March 2022 as against Rs 600.75 crore during the previous quarter ended March 2021. For the full year, net profit rose 160.14% to Rs 308.87 crore in the year ended March 2022 as against Rs 118.73 crore during the previous year ended March 2021. Sales rose 7.27% to Rs 1988.46 crore in the year ended March 2022 as against Rs 1853.66 crore during the previous year ended March 2021.

Raymond

Raymond Ltd reported over four-fold jump in its consolidated net profit to Rs 264.97 crore for the fourth quarter ended in March 2022, helped by a buoyant demand and strong consumer sentiments during the period. The company had posted a net profit of Rs 58.36 crore during the January-March quarter of the previous fiscal. Its revenue from operations was up 43.38 per cent to Rs 1,958.10 crore during the quarter under review as against Rs 1,365.66 crore in the corresponding period of the previous fiscal. Its total expenses were at Rs 1,790.12 crore, up 33.36 per cent in Q4/FY 2021-22, as against Rs 1,342.31 crore in the year-ago quarter.

Abbott India

Net profit of Abbott India rose 38.66% to Rs 211.41 crore in the quarter ended March 2022 as against Rs 152.47 crore during the previous quarter ended March 2021. Sales rose 14.56% to Rs 1255.02 crore in the quarter ended March 2022 as against Rs 1095.54 crore during the previous quarter ended March 2021. For the full year, net profit rose 15.64% to Rs 798.70 crore in the year ended March 2022 as against Rs 690.69 crore during the previous year ended March 2021. Sales rose 14.14% to Rs 4919.27 crore in the year ended March 2022 as against Rs 4310.02 crore during the previous year ended March 2021.

Indoco Remedies

Net profit of Indoco Remedies rose 61.80% to Rs 40.45 crore in the quarter ended March 2022 as against Rs 25.00 crore during the previous quarter ended March 2021. Sales rose 35.72% to Rs 400.52 crore in the quarter ended March 2022 as against Rs 295.10 crore during the previous quarter ended March 2021. For the full year, net profit rose 66.36% to Rs 154.80 crore in the year ended March 2022 as against Rs 93.05 crore during the previous year ended March 2021. Sales rose 23.40% to Rs 1503.73 crore in the year ended March 2022 as against Rs 1218.61 crore during the previous year ended March 2021.

Dodla Dairy

Dodla Dairy reported net profit zoomed to Rs 40.5 crore in Q4 FY22 from Rs 9.6 crore in Q4 FY21. Operating revenues increased by 11% to Rs 589.7 crore in Q4 FY22 over Q4 FY21. The average milk procurement during Q4 FY22 was at 12.3 lakhs liters per day (LLPD) compared to 10.8 LLPD in Q4 FY21 and 12.4 LLPD in Q3 FY22. Average milk sales during Q4 FY22 were at 9.7 LLPD compared to 9.2 LLPD in Q4 FY21 and 9.9 LLPD in Q3 FY22. Curd sales during Q4 FY22 was at 288 MTPD compared to 266 MTPD in Q4 FY21 and 245 MTPD in Q3 FY22. Revenue from value added products (VAP) excluding fat & fat-based products was at Rs 140.6 crore contributing 24% to the overall dairy revenue during Q4 FY22 compared to Rs 119.2 crore contributing 21% to the overall dairy revenue during Q3 FY22. Profit before tax in Q4 FY22 stood at Rs 37.71 crore, up by 56.5% from Rs 24.09 crore in Q4 FY21.

Bajaj Electricals

Bajaj Electricals reported 28.7% fall in consolidated net profit to Rs 39 crore despite a 6% rise in net sales to Rs 1,293.26 crore in Q4 FY22 over Q4 FY21. On the segmental front, Consumer Products revenue was Rs 1,038 crore (up 6.4% YoY) while EPC revenue stood at Rs 296.5 crore (up 4.7% YoY) in the fourth quarter of financial year ended 2022. Profit before tax in Q4 FY22 stood at Rs 56 crore, down by 25.4% from Rs 75 crore posted in Q4 FY21. Total expenses were up by 7% year on year to Rs 1,299.61 crore in the financial year ended 31 March 2022. On full year basis, the electrical appliances company reported 32.55% decline in consolidated net profit to Rs 128.52 crore on despite of 3.9% rise in net sales to Rs 4,727.69 crore in the financial year ended 31 March 2022 over the financial year ended 31 March 2021.

Analyst Certification:

We /I, Jaydeb Dey and Shreyansh N. Mehta Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
